← Back to Screener
Medpace Holdings, Inc. Common Stock (MEDP)
Price$528.44
Favorite Metrics
Price vs S&P 500 (26W)-4.88%
Price vs S&P 500 (4W)5.55%
Market Capitalization$14.87B
P/E Ratio (Annual)32.96x
All Metrics
P/CF (Annual)20.85x
Book Value / Share (Quarterly)$16.22
P/TBV (Annual)37.17x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)20.12%
Cash Flow / Share (Quarterly)$24.09
Price vs S&P 500 (YTD)-11.45%
Gross Margin (TTM)30.06%
Net Profit Margin (TTM)17.83%
EPS (TTM)$15.29
10-Day Avg Trading Volume0.37M
EPS Excl Extra (TTM)$15.29
Revenue Growth (5Y)22.27%
EPS (Annual)$15.28
ROI (Annual)98.27%
Gross Margin (Annual)30.06%
Net Profit Margin (5Y Avg)16.94%
Cash / Share (Quarterly)$17.56
P/E Basic Excl Extra (TTM)32.96x
Revenue Growth QoQ (YoY)32.03%
EPS Growth (5Y)31.70%
P/E Normalized (Annual)32.96x
ROA (Last FY)22.84%
Revenue Growth TTM (YoY)19.97%
EBITD / Share (TTM)$18.88
ROE (5Y Avg)56.09%
Operating Margin (TTM)21.14%
Cash Flow / Share (Annual)$24.09
P/B Ratio32.39x
P/B Ratio (Quarterly)34.46x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)5.68x
Net Interest Coverage (TTM)139.88x
ROA (TTM)25.07%
EPS Growth QoQ (YoY)27.03%
EV / EBITDA (TTM)25.77x
EPS Incl Extra (Annual)$15.28
Current Ratio (Annual)0.74x
Quick Ratio (Quarterly)0.67x
3-Month Avg Trading Volume0.32M
52-Week Price Return75.58%
EV / Free Cash Flow (Annual)21.07x
P/E Incl Extra (TTM)32.96x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$15.04
P/S Ratio (Annual)5.88x
Asset Turnover (Annual)1.28x
52-Week High$628.92
Operating Margin (5Y Avg)19.33%
EPS Excl Extra (Annual)$15.28
CapEx CAGR (5Y)0.04%
Tangible BV CAGR (5Y)-10.93%
26-Week Price Return3.87%
Quick Ratio (Annual)0.67x
13-Week Price Return-15.55%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.74x
Enterprise Value$14,370.266
Revenue / Share Growth (5Y)28.39%
Asset Turnover (TTM)1.41x
Book Value / Share Growth (5Y)-6.50%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)21.44%
Cash / Share (Annual)$17.56
3-Month Return Std Dev46.75%
Gross Margin (5Y Avg)29.47%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)24.68%
EBITDA Interim CAGR (5Y)21.63%
ROE (Last FY)98.27%
Net Interest Coverage (Annual)100.53x
EPS Basic Excl Extra (Annual)$15.28
P/FCF (TTM)21.80x
Receivables Turnover (TTM)7.24x
EV / Free Cash Flow (TTM)21.07x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$15.29
Receivables Turnover (Annual)7.24x
ROI (TTM)118.82%
P/S Ratio (TTM)5.88x
Pretax Margin (5Y Avg)19.77%
Revenue / Share (Annual)$85.69
Tangible BV / Share (Annual)$15.04
Forward P/E30.80x
Free OCF CAGR (5Y)24.56%
Price vs S&P 500 (52W)40.49%
P/E Ratio (TTM)32.96x
EPS Growth TTM (YoY)21.01%
Year-to-Date Return-7.31%
5-Day Price Return3.86%
EPS Normalized (Annual)$15.28
ROA (5Y Avg)17.65%
Net Profit Margin (Annual)17.83%
Month-to-Date Return8.42%
Cash Flow / Share (TTM)$9.33
EBITD / Share (Annual)$19.15
EPS Growth (3Y)28.02%
Operating Margin (Annual)21.14%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)20.85x
ROI (5Y Avg)54.63%
P/E Excl Extra (TTM)32.96x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$15.29
P/TBV (Quarterly)37.17x
P/B Ratio (Annual)34.46x
Pretax Margin (TTM)21.44%
Book Value / Share (Annual)$16.22
Price vs S&P 500 (13W)-18.41%
Net Margin Growth (5Y)2.58%
Beta1.37x
P/FCF (Annual)21.80x
Revenue / Share (TTM)$87.32
ROE (TTM)118.82%
52-Week Low$250.05
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.61
2.61
3.53
3.60
Industry Peers — R&D — Physical Sciences(9)
| Symbol | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|
MEDPMedpace Holdings, Inc. Common Stock | 32.96x | 118.82% | 22.27% | — | $528.44 |
IQVIQVIA Holdings Inc. | 22.06x | 22.28% | 7.50% | — | $176.76 |
INCYIncyte Genomics Inc | 15.00x | 29.15% | 14.03% | — | $96.92 |
CRLCharles River Laboratories International, Inc. | — | -4.40% | 6.55% | — | $185.54 |
ABSIAbsci Corporation Common Stock | — | -59.68% | -10.14% | — | $3.95 |
NRCNational Research Corporation Common Stock (Delaware) | 35.35x | 58.51% | 0.61% | 3.55% | $18.18 |
OABIOmniAb, Inc. Common Stock | — | -23.99% | -4.31% | — | $1.55 |
MXCTMaxCyte, Inc. Common Stock | — | -24.06% | 4.76% | — | $0.86 |
NOTVInotiv, Inc. Common Stock | — | -50.77% | 53.35% | — | $0.29 |
ISPCiSpecimen Inc. Common Stock | — | -496.37% | -25.09% | — | $0.13 |
About
Medpace is a late-stage contract research organization providing comprehensive drug development and clinical trial services to small and midsize biotech, pharmaceutical, and medical device companies. The company offers additional capabilities including bioanalytical laboratory services and imaging solutions. With over 5,400 employees across 40 countries and 30+ years of industry experience, Medpace maintains global operations headquartered in Cincinnati, Ohio, with a substantial presence across North America, Europe, Asia, and other regions.